$2.2 M

IMUC Mkt cap, 16-Oct-2018
ImmunoCellular Therapeutics Net income (Q2, 2018)-306.7 K
ImmunoCellular Therapeutics Cash, 30-Jun-20182.9 M

ImmunoCellular Therapeutics Income Statement

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

R&D expense

5.3m10.9m19.1m17.1m

General and administrative expense

3.4m4.6m5.0m4.0m

Operating expense total

9.5m15.5m24.1m21.2m

Interest expense

133.9k1.3m882.7k

Interest income

17.3k19.9k24.4k4.7k

Pre tax profit

(8.8m)(14.3m)

Net Income

(8.8m)(12.8m)(22.1m)(14.3m)

Quarterly

ImmunoCellular Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

27.6m22.6m11.4m6.6m

Current Assets

28.4m24.6m13.4m7.0m

PP&E

66.4k180.9k109.8k568.0

Total Assets

28.9m30.1m16.9m7.0m

Accounts Payable

861.0k1.2m1.3m1.8m

Current Liabilities

1.4m2.3m3.2m2.4m

Total Liabilities

8.4m10.8m2.4m

Additional Paid-in Capital

78.4m95.8m102.4m121.1m

Retained Earnings

(74.1m)(96.2m)(116.4m)

Total Equity

21.7m6.1m4.6m

Financial Leverage

1.4 x2.8 x1.5 x

ImmunoCellular Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(8.8m)(12.8m)(22.1m)(14.3m)

Depreciation and Amortization

50.4k36.2k75.1k47.8k

Accounts Payable

128.2k805.3k125.4k491.0k

Cash From Operating Activities

(8.8m)(19.0m)(19.9m)(16.7m)

Purchases of PP&E

(44.4k)(169.7k)(4.0k)

Cash From Investing Activities

(44.4k)(169.7k)(4.0k)1.3k

Cash From Financing Activities

10.3m18.6m8.7m11.9m

Quarterly

USDQ2, 2014Q3, 2015Q2, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(5.4m)(8.0m)(11.0m)(5.8m)(9.4m)(1.0m)(1.3m)

Depreciation and Amortization

23.9k20.3k41.0k16.6k33.2k106.0212.0

Accounts Payable

(239.1k)535.6k(531.5k)(518.4k)2.8m(649.7k)(1.7m)

Cash From Operating Activities

(5.3m)(13.2m)(11.2m)(6.1m)(9.5m)(1.6m)(3.8m)

Purchases of PP&E

(3.6k)(169.7k)(4.0k)

Cash From Investing Activities

(3.2k)(169.7k)(4.0k)

Cash From Financing Activities

3.3m14.6m542.5k(25.3k)(99.9k)

ImmunoCellular Therapeutics Ratios

USDY, 2018

Financial Leverage

1.1 x